[ad_1]
A final analysis of the phase 3 study of the COVID vaccine produced by Pfizer and BioNTech shows that it was 95% effective in preventing infections, even in older adults, and did not cause serious safety concerns, the company said Wednesday. , according to CNN.
The studies reported 170 cases of coronavirus infection among volunteers who participated in the tests. Of these cases, 162 infections occurred in people who received placebo or plain saline vaccines, while eight were in participants who received the vaccine itself. This results in an efficiency of 95%, says the American company Pfizer.
Initial data showed an efficiency of more than 90%. Subsequently, the Russians claimed that the Sputnik V vaccine is 92% effective, while the manufacturer Moderna claimed that the produced vaccine is 95% effective.
“Efficacy was consistent by age, race and ethnicity. The effectiveness observed in adults over 65 years was greater than 94%,” said Pfizer and its German partner BioNTech in a joint statement.
“10 severe cases of COVID-19 were observed in the trial, nine of which occurred in the placebo group and one in the vaccinated group,” the two companies said.
An independent group followed the results and side effects. “To date, the Study Follow-up Committee has not reported any serious safety concerns related to the vaccine.”
The only “adverse element” was fatigue in 3.7% of the patients.
The companies have announced that they will apply to the US authorities for emergency approval of the vaccine in the coming days. The data will also be passed on to other regulators around the world.
“The rapid protection this vaccine offers, combined with its tolerability profile across all age groups studied so far, should help make this vaccine an important tool in addressing the current pandemic,” said Dr. Ugur Sahin. , CEO and co-founder of BioNTech.
Based on current forecasts, companies expect to produce up to 50 million doses of vaccines globally in 2020 and up to 1.3 billion doses in 2021.
Publisher: RK
